Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...

Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.

Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...

Specific subtypes and transmission clusters for HIV could require targeted interventions to control spread of HIV that is ...

“We are talking about sex and drugs—two topics that people call taboo,” said Brigitte Quenum, UNAIDS Regional Team Lead for ...

A University of New Mexico researcher and assistant professor is breaking barriers in the health community for fellow Native Americans. Hailing from the Diné Nation, Crystal Lee has been researching ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Gammora was shown to be safe and effective in eliminating HIV-infected cells without harming surrounding uninfected cells, ...

The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Most recently, the HIV community has been very excited about a new PrEP drug called lenacapavir. This is an injectable form of PrEP that only needs to be given every six months. In trials among ...